HER2
42 programs · 42 companies
Programs
42
Companies
42
Active Trials
30
Targeting HER2
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | Hemophilia AHeart Failure | |
| VRT-4938 | Vertex Pharma | Preclinical | Gastric CaPBC | |
| ROI-9675 | Roivant Sciences | NDA/BLA | IPF | |
| ELV-1411 | Enliven | NDA/BLA | MCCSLE | |
| Zoricapivasertib | CSL Limited | Phase 2 | ALLEoE | |
| Semaosocimab | PharmaEssentia | Phase 2/3 | PNHDLBCL | |
| NCI-IIT-143 | NCI | Phase 1/2 | ALL | |
| EOR-IIT-783 | EORTC | Phase 3 | CKD | |
| AFF-3518 | Affinia Ther | Phase 1 | CeliacALS | |
| ACI-6417 | AC Immune | Phase 2/3 | PompePNH | |
| Adagralemzoparlimab | Applied Ther | Approved | MigrainePV | |
| IMA-217 | Imago BioSciences | NDA/BLA | HSWM | |
| BLP-8287 | Bellerophon | NDA/BLA | UCPBC | |
| Zoriosocimab | Aveo Pharma (LG Chem) | Phase 2 | Psoriasis | |
| AVI-386 | Atea Pharma | Phase 1/2 | TTR AmyloidosisCRC | |
| CHI-1577 | China Biologic | Phase 2/3 | MigraineNarcolepsy | |
| Zanutapinarof | Connect Biopharma | Approved | MesoCervical Ca | |
| PRE-6102 | Prevail (Lilly) | Preclinical | CSU | |
| 996-5071 | Alphamab | Phase 1/2 | Schizophrenia | |
| DAS-562 | Dasan Zhone | Approved | RCC | |
| Cevilemzoparlimab | Totus Med | Preclinical | NMOSD | |
| Semasertib | Tarsus Pharma | Phase 2 | ALSUC | |
| Polamavacamten | StrideBio | NDA/BLA | Fabry | |
| IST-1205 | Istari Onc | Phase 2 | ThymomaMyelofibrosis | |
| Ivorasimod | Modalis Ther | Phase 3 | SLEFabry | |
| Fixalucimab | Genfit | NDA/BLA | CMLGIST | |
| Kemasacituzumab | Boehringer | Approved | CTCL | |
| Rilusertib | Affimed | Phase 3 | CeliacCrohn's | |
| Ribosotorasib | Starpharma | Approved | DLBCLAsthma | |
| Polavorutinib | Acerus (Sun) | Phase 3 | ThymomaNASH | |
| NEO-5036 | NeoGenomics | Phase 1/2 | PAHCLL | |
| Tezebrutinib | Tessa Therapeutics | Preclinical | LGSAtopic Derm | |
| 416-1749 | PharmaEngine | Preclinical | MDS | |
| 415-7241 | TaiGen Biotherapeutics | Phase 1 | CFCRC | |
| DIV-9629 | Divi's Laboratories | Phase 3 | Urothelial Ca | |
| BIO-IIT-896 | Bio Farma | Phase 1/2 | PsA | |
| NAT-IIT-330 | Natl Cancer Ctr Singapore | Phase 2 | GBM | |
| Tiratuximab | Walvax Biotech | Phase 2 | Heart Failure | |
| Doxacilimab | Bruker | NDA/BLA | CholangiocarcinomaHCC | |
| Cevisotorasib | Neogen | Phase 2/3 | LNGA | |
| VEE-9538 | Veeva Systems | Phase 1 | Prostate CaCeliac | |
| YB-3612 | Y Biologics | Phase 1 | IPFTTR Amyloidosis |